Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy in patients with congenital hypogonadotropic hypogonadism: a multicentre clinical study.

ABSTRACT:

Background

Pulsatile gonadotropin-releasing hormone (GnRH) therapy may restore function of the hypothalamus-pituitary-gonad axis and induce spermatogenesis in male patients with congenital hypogonadotropic hypogonadism (CHH). The study sought to test the reliability of a newly developed Innopump^® hormone pump, and to confirm the efficacy and safety of pulsatile GnRH therapy (by Innopump^® hormone pump) in CHH patients.

Methods

From November 2017 to November 2018, 28 male patients with CHH were treated with pulsatile GnRH at Peking Union Medical College Hospital, Beijing Chaoyang Hospital, and Shandong Provincial Hospital. A prospective, self-controlled, 7-day clinical trial was conducted. The primary outcome measures were the efficacy and safety of pulsa

SUBMITTER: Hao M 

PROVIDER: S-EPMC8267282 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature